2024
Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis.
Nassar A, Matteson K, Ardeshir F, Gray J, Baena Espinar J, Kwiatkowski D, Aboubakar Nana F, Grohe C, Citarella F, Pancirer D, Cheung J, Watson A, Sridhar A, Crowley F, Kaldas D, Kim C, Sankar K, Awosika N, Naqash A, Chiang A. Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis. Journal Of Clinical Oncology 2024, 42: 8106-8106. DOI: 10.1200/jco.2024.42.16_suppl.8106.Peer-Reviewed Original ResearchLarge cell neuroendocrine carcinomaProgression-free survivalTreatment-related adverse eventsPD-L1 statusOverall survivalPD-L1Systemic therapyRetrospective analysisGrades treatment-related adverse eventsTreatment approachesCell neuroendocrine carcinomaMedian follow-upMulticenter retrospective analysisTreated with chemotherapySystemic treatment approachesChemo-regimenPlatinum-etoposideNeuroendocrine carcinomaOS outcomesLine treatmentToxicity profileClinical outcomesAdverse eventsImmunotherapyIO groupComparison of chemotherapy to chemo-immunotherapy as first-line treatment in patients with advanced large cell neuroendocrine carcinomas (LCNECs) of mixed histology: A multi-institutional international retrospective study.
Matteson K, Nassar A, Ellis-Caleo T, Mingo E, Aggarwal V, Sridhar A, Alam S, Crowley F, Aboubakar Nana F, Ahmed M, Grohe C, Zurera Berjaga M, Pinato D, Watson A, Chiang A, Naqash A. Comparison of chemotherapy to chemo-immunotherapy as first-line treatment in patients with advanced large cell neuroendocrine carcinomas (LCNECs) of mixed histology: A multi-institutional international retrospective study. Journal Of Clinical Oncology 2024, 42: 8602-8602. DOI: 10.1200/jco.2024.42.16_suppl.8602.Peer-Reviewed Original ResearchProgression-free survivalTreatment-related adverse eventsFirst-line treatmentMedian progression-free survivalOverall survivalChemo-immunotherapyMedian OSLung cancerAll-grade treatment-related adverse eventsRare subtype of lung cancerMulti-institutional retrospective analysisSmall cell lung cancerCell neuroendocrine carcinomaInternational retrospective studyCell lung cancerSubtype of lung cancerLog-rank testFeatures of adenocarcinomaOptimal treatment approachClinical trial dataChemo-regimensNeuroendocrine carcinomaChemo groupSystemic therapyRare subtypeAbstract 971: Validation of a tumor-naïve circulating tumor DNA (ctDNA) response monitoring panel in advanced non-small cell lung cancer (aNSCLC)
Chiang A, Madison R, Huang Y, Fine A, Jin D, Oxnard G, Hughes J, Assaf Z, Cao Y, Antic V, Gjoerup O, Young A, Fabrizio D, Lakhanpal S, Zuniga R, Schulze K, Pasquina L. Abstract 971: Validation of a tumor-naïve circulating tumor DNA (ctDNA) response monitoring panel in advanced non-small cell lung cancer (aNSCLC). Cancer Research 2024, 84: 971-971. DOI: 10.1158/1538-7445.am2024-971.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerPeripheral blood mononuclear cellsNon-small cell lung cancerRisk of progressionCell lung cancerClonal hematopoiesisTumor fractionGenomic alterationsTumor signalAmerican Association for Cancer Research annual meetingsLung cancerHazard ratioPatient's risk of progressionFrequency of genomic alterationsAssociated with favorable outcomesMolecular responseWeeks of TxProgression free survivalUnivariate Cox proportional hazards regressionCox proportional hazards regressionBlood mononuclear cellsConfidence intervalsVariant allele frequencyCombination of aneuploidyProportional hazards regression214TiP Tarlatamab after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC): DeLLphi-306 (NCT06117774)
Hummel H, Paz-Ares L, Blackhall F, Chiang A, Dowlati A, Goldman J, Izumi H, Mok T, Sands J, Martinez P, Anderson E, Bharania P, Yu B, Yu Y, Pulla M. 214TiP Tarlatamab after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC): DeLLphi-306 (NCT06117774). ESMO Open 2024, 9: 102787. DOI: 10.1016/j.esmoop.2024.102787.Peer-Reviewed Original Research
2023
Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex
Jairam V, Soulos P, Madhav K, Gross C, Slotman B, Chiang A, Park H. Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex. Advances In Radiation Oncology 2023, 9: 101413. PMID: 38778819, PMCID: PMC11110031, DOI: 10.1016/j.adro.2023.101413.Peer-Reviewed Original ResearchExtensive-stage small-cell lung cancerConsolidative thoracic radiotherapyProgression-free survivalSmall cell lung cancerCell lung cancerCREST trialThoracic radiotherapyLung cancerElectronic health record-derived databaseFirst-line systemic therapyStandard first-line treatmentCox proportional hazards regressionFirst-line treatmentNational practice patternsProportional hazards regressionSuperior OSInitial chemotherapyBaseline characteristicsSystemic therapyMale patientsFemale patientsPatient sexHazards regressionSurvival outcomesPractice patternsMA15.07 NC318, an Anti-Siglec-15 Humanized mAb, Alone and in Combination with Pembrolizumab in Immunotherapy Pretreated NSCLC
Gettinger S, Goldberg S, Chiang A, Wilson F, Kim S, Rowen E, Gerrish H, Duffield E, Davies M, Dest V, Jackson R, Pope J, Myint H, Langermann S, Cheng W, Rimm D, Chen L, Herbst R. MA15.07 NC318, an Anti-Siglec-15 Humanized mAb, Alone and in Combination with Pembrolizumab in Immunotherapy Pretreated NSCLC. Journal Of Thoracic Oncology 2023, 18: s155. DOI: 10.1016/j.jtho.2023.09.224.Peer-Reviewed Original ResearchMutation-specific costs of advanced non-small cell lung cancer treatment.
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Mutation-specific costs of advanced non-small cell lung cancer treatment. JCO Oncology Practice 2023, 19: 14-14. DOI: 10.1200/op.2023.19.11_suppl.14.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerNon-small cell lung cancerMean medication costsActionable gene alterationsMedication costsFirst-year costsReference groupAdvanced non-small cell lung cancer (NSCLC) treatmentNon-small cell lung cancer (NSCLC) treatmentCell lung cancer treatmentGene alterationsBiomarker resultsFlatiron Health databasePD-L1 resultsTherapy prolongs survivalRetrospective cohort studyCell lung cancerBiomarker test resultsLung cancer treatmentCost-effectiveness analysisCohort studyNovel immunotherapiesOverall cohortProlong survivalTreatment optionsUsing real world practice patterns to identify clinical equipoise in cancer treatment: Advanced non-small cell lung cancer as an exemplar.
Li Y, Yang S, Chiang A, Gross C, Wang S. Using real world practice patterns to identify clinical equipoise in cancer treatment: Advanced non-small cell lung cancer as an exemplar. JCO Oncology Practice 2023, 19: 539-539. DOI: 10.1200/op.2023.19.11_suppl.539.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerPD-L1 1First-line therapyCell lung cancerTreatment patternsECOG 2PD-L1Clinical equipoiseLung cancerHHI scoresEastern Cooperative Oncology Group performance scoreFirst-line treatment regimensReal-world practice patternsALK/EGFRActionable gene alterationsStandard of careConfidence intervalsGroup performance scoreComparative effectiveness researchECOG statusOverall cohortPerformance statusECOG scoreTreatment regimensThe effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.
Mack P, Redman M, Kozono D, Callis S, Tukachinsky H, Tolba K, Neal J, Waqar S, Dragnev K, Aggarwal C, Hirsch F, Patel J, Herbst R, Chiang A, Reckamp K, Kelly K, Borghaei H, Gray J, Gandara D. The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP. Journal Of Clinical Oncology 2023, 41: 9035-9035. DOI: 10.1200/jco.2023.41.16_suppl.9035.Peer-Reviewed Original Research145MO Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study
Carbone D, Waqar S, Chaft J, Kris M, Johnson B, Lee J, Wistuba I, Kwiatkowski D, Bunn P, Schulze K, Johnson A, Brandao E, Awad M, Reckamp K, Chiang A, Nicholas A, Rusch V. 145MO Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study. Journal Of Thoracic Oncology 2023, 18: s90-s91. DOI: 10.1016/s1556-0864(23)00339-8.Peer-Reviewed Original ResearchAssociations of Early Completion of Advance Directives With Key End-of-Life Quality Measures: Analysis of an ASCO Quality Oncology Practice Initiative Patient Cohort
Power S, Bickel K, Chen R, Chiang A, Garrett-Mayer L, Makhoul I, Mougalian S, Shapiro C, Siegel R, Smith C, Rocque G, Kozlik M, Crist S, Kamal A. Associations of Early Completion of Advance Directives With Key End-of-Life Quality Measures: Analysis of an ASCO Quality Oncology Practice Initiative Patient Cohort. JCO Oncology Practice 2023, 19: e520-e526. PMID: 36669136, DOI: 10.1200/op.22.00464.Peer-Reviewed Original ResearchConceptsDays of lifeEmergency room visitsAD completionChemotherapy receiptRoom visitsAdvance directivesIntensive care unit admissionLife quality measuresCare unit admissionEOL quality measuresOutcomes of patientsIntensive care unitPatient-level dataChi-square testHigh rateUnit admissionHospice enrollmentCare unitOncology visitsPatient cohortPatient enrollmentPatientsCancer diagnosisVisitsQuality measures
2022
Oral Chemotherapy Metric Performance in Quality Oncology Practice Initiative Practices: Updated Trends and Analysis.
Blinder VS, Garrett-Mayer E, Jacobsen PB, Kozlik MM, Markham MJ, Siegel RD, Kamal AH, Crist STS, Rosenthal J, Chiang AC, _ _. Oral Chemotherapy Metric Performance in Quality Oncology Practice Initiative Practices: Updated Trends and Analysis. Journal Of The National Comprehensive Cancer Network 2022, 20: 1099-1106.e2. PMID: 36240846, DOI: 10.6004/jnccn.2022.7024.Peer-Reviewed Original ResearchEP16.02-002 Circulating Tumor DNA (ctDNA) Changes in Patients With Lung Cancer from a Real-World Prospective Clinico-Genomic (PCG) Study
Chiang A, Kaur M, Assaf Z, Fine A, Zhao Y, Cao Y, Madison R, Oxnard G, Tolba K, Zuniga R, Lakhanpal S, Antic V, Bourla A, Schulze K. EP16.02-002 Circulating Tumor DNA (ctDNA) Changes in Patients With Lung Cancer from a Real-World Prospective Clinico-Genomic (PCG) Study. Journal Of Thoracic Oncology 2022, 17: s571-s572. DOI: 10.1016/j.jtho.2022.07.1033.Peer-Reviewed Original ResearchKeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.
Sands J, Reck M, Navarro A, Chiang A, Lu S, Peled N, Paz-Ares L, Kerr S, Takahashi T, Smolin A, Chen X, Zhao B, El-Osta H, Califano R. KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer. Journal Of Clinical Oncology 2022, 40: tps8606-tps8606. DOI: 10.1200/jco.2022.40.16_suppl.tps8606.Peer-Reviewed Original ResearchExtensive-stage small-cell lung cancerEtoposide/platinumPatient-reported outcomesSmall cell lung cancerPhase 3 studyLung cancerRECIST v1.1ECOG PSDisease progressionBlinded independent central reviewNeurologic paraneoplastic syndromesUntreated ES-SCLCFirst-line pembrolizumabFirst-line treatmentInterstitial lung diseaseCell lung cancerDuration of responseT cell immunoreceptorIndependent central reviewWithdrawal of consentPretreatment tumor samplesNew anticancer treatmentsCare immunotherapyCTCAE v5.0Measurable diseasePlenary Session—The Patient Journey: Access to Cancer Care
Hammon D, Souza E, Chiang A, Shulman L, Kubal T. Plenary Session—The Patient Journey: Access to Cancer Care. Journal Of The National Comprehensive Cancer Network 2022, 20: 1-4. DOI: 10.6004/jnccn.2022.5011.Peer-Reviewed Original ResearchHematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice Initiative
Makhoul I, Anders M, Siegel R, Chiang A, Markham MJ, Chen RC, Mougalian S, Arnaoutakis K, Giuliani M, Im A, Kozlik MMP, Crist STS, Garrett-Mayer E, Kamal A. Hematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice Initiative. JCO Oncology Practice 2022, 18: e1209-e1218. PMID: 35467961, DOI: 10.1200/op.21.00807.Peer-Reviewed Original ResearchConceptsQuality Oncology Practice InitiativeEducational benefitsQI projectQuality improvement projectElectronic medical recordsPractice initiativesQI participationGraduate Medical Education requirementsFellowship programsMedical Education requirementsManual data abstractionMedical recordsMajority of programsOncology ProgramOncology fellowsACGME standardsEducation requirementsFaculty involvementAccreditation CouncilLongitudinal reportsRelationship Between Participation in ASCO's Quality Oncology Practice Initiative Program and American Board of Internal Medicine's Maintenance of Certification Program
Siegel RD, Garrett-Mayer E, Lipner RS, Kozlik MMP, Vandergrift JL, Crist STS, Chen RC, Chiang AC, Kamal AH, Force O. Relationship Between Participation in ASCO's Quality Oncology Practice Initiative Program and American Board of Internal Medicine's Maintenance of Certification Program. JCO Oncology Practice 2022, 18: e1350-e1356. PMID: 35363501, DOI: 10.1200/op.21.00777.Peer-Reviewed Original ResearchConceptsQuality Oncology Practice InitiativeInternal Medicine MaintenanceMedical oncologistsCancer care deliveryUS medical oncologistsHigh-quality patient careAmerican BoardPatient careCare deliveryOncologistsPractice levelIndividual basisPractice initiativesAssociationProficiency programPersonal factorsVariety of optionsIndividual practicesPhysiciansASCOPre-Treatment Staging Imaging in Rectal Cancer: Results From the Quality Oncology Practice Initiative
Chen RC, Garrett-Mayer E, Kamal AH, Makhoul I, Kozlik MMP, Crist STS, Chiang AC, Force O. Pre-Treatment Staging Imaging in Rectal Cancer: Results From the Quality Oncology Practice Initiative. JCO Oncology Practice 2022, 18: e1367-e1373. PMID: 35353546, DOI: 10.1200/op.21.00455.Peer-Reviewed Original ResearchConceptsQuality Oncology Practice InitiativeRectal cancerTime pointsASCO's Quality Oncology Practice InitiativeNational Comprehensive Cancer Network guidelinesPelvic magnetic resonance imagingNonmetastatic rectal cancerPre-treatment stagingThird of patientsAssessment time pointsRandom-effects modelMagnetic resonance imagingPractice initiativesSubsequent time pointsQuality improvement effortsInitial therapyInitial stagingAppropriate imagingStaging scansNetwork guidelinesUnique patientsOptimal treatmentCare coordinationN stagingEndorectal ultrasoundCOVID-19 and Cancer Center Operations: Lessons Learned From the NCCN Best Practices Committee.
Sugalski JM, Franco T, Shulman LN, Souza E, Hochberg E, Chiang A, Lawrence S, Krause D, Kubal T. COVID-19 and Cancer Center Operations: Lessons Learned From the NCCN Best Practices Committee. Journal Of The National Comprehensive Cancer Network 2022, 20: 1-4. PMID: 34991065, DOI: 10.6004/jnccn.2021.7102.Peer-Reviewed Original Research
2021
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2021, 19: 1441-1464. PMID: 34902832, DOI: 10.6004/jnccn.2021.0058.Peer-Reviewed Original Research